Dechert Advises Existing Investors in Enyo Pharma's €40M Series B Fundraising
PARIS – Dechert LLP advised the existing investors, Sofinnova Partners, Morningside Ventures Investments Limited, Bpifrance Investissement (Innobio) and Inserm Transfert Initiative, in the context of a €40 million new Series B financing round of Enyo Pharma.
The new investors are OrbiMed (lead investor), Andera Partners (ex-EdRIP) and Bpifrance Large Venture.
Enyo Pharma, headquartered in Lyon, is a clinical stage biotech company developing innovative drug candidates by mimicking virus strategies to modulate host cellular functions.
This new funding will enable Enyo Pharma to pursue the Phase II clinical development of its lead compound in two indications of major liver infections (chronic hepatitis and NASH). In addition, Enyo Pharma will continue to develop its early pipeline by bringing at least one of its other proprietary compounds to Phase I studies.
The existing investors were advised by Dechert’s Paris team led by Anne-Charlotte Rivière assisted by Laurent Kocimski. The firm has developed an expertise in private equity and venture capital transactions with a particular sector focus on life sciences and biotech.
Read the French press release »
About Dechert
Dechert is a leading global law firm with 27 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.
